Quantcast

Latest Low-Grade Serous Ovarian Cancer Stories

2014-05-14 08:30:37

BOULDER, Colo., May 14, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on its MEK inhibitors, binimetinib (MEK162) (co-developing with Novartis) and selumetinib (licensed to AstraZeneca) at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 30 - June 3, 2014 in Chicago, Illinois. Both MEK inhibitors are advancing in Phase 3 or pivotal trials: binimetinib is being evaluated in NRAS- and BRAF-mutant...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'